Clinical Trial

Clinical Trial of PCV24 in Adults Aged ≥18 Years

Name: Clinical Trial of PCV24 in Adults Aged ≥18 Years — clinical trial record (NCT07543198)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1/2

View on ClinicalTrials.gov →

Summary

A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged ≥18 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, Positive Controlled phase Ib/II clinical trial.

Trial Details

NCT Number	NCT07543198
Lead Sponsor	Sinovac Life Sciences Co., Ltd.
Conditions	Pneumococcal Infectious Disease
Enrollment	385 participants
Start Date	2025-06-18
Primary Completion	2026-02-26 (estimated)
Study Completion	2026-02-26 (estimated)
Updated on ClinicalTrials.gov	2026-04-21